Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J HIRSH

Showing results (661-670 of 666) with videos related to

Pageof 67
Sort By:
You have reached the last page of results.This site can display upto 666 results.
Development (Cambridge, England)|August 19, 2007
beta-catenin/TCF/Lef controls a differentiation-associated transcriptional program in renal epithelial progenitorsKai M Schmidt-Ott, T Nestor H Masckauchan, Xia Chen, et al.
Lancet (London, England)|January 13, 1973
Australian multicentre trial of streptokinase in acute myocardial infarctionJ H Bett, P A Castaldi, G S Hale, et al.
Annals of Internal Medicine|June 1, 1983
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scanR D Hull, J Hirsh, C J Carter, et al.
Journal of Medicinal Chemistry|July 11, 2006
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitisAndrew J Hirsh, Bruce F Molino, Jianzhong Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 26, 2008
Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung diseaseAndrew J Hirsh, Jim Zhang, Andra Zamurs, et al.
Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factorC Kearon, J S Ginsberg, D R Anderson, et al.
Pageof 67

Showing results (661-670 of 666) with videos related to

Sort By:
Pageof 67
You have reached the last page of results.This site can display upto 666 results.
Development (Cambridge, England)|August 19, 2007
beta-catenin/TCF/Lef controls a differentiation-associated transcriptional program in renal epithelial progenitorsKai M Schmidt-Ott, T Nestor H Masckauchan, Xia Chen, et al.
Lancet (London, England)|January 13, 1973
Australian multicentre trial of streptokinase in acute myocardial infarctionJ H Bett, P A Castaldi, G S Hale, et al.
Annals of Internal Medicine|June 1, 1983
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scanR D Hull, J Hirsh, C J Carter, et al.
Journal of Medicinal Chemistry|July 11, 2006
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitisAndrew J Hirsh, Bruce F Molino, Jianzhong Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 26, 2008
Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung diseaseAndrew J Hirsh, Jim Zhang, Andra Zamurs, et al.
Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factorC Kearon, J S Ginsberg, D R Anderson, et al.
Pageof 67